ZS’s John Piccone sees an opportunity for biomedical research

The pharmaceutical industry is experiencing an explosion of scientific information shaking them out of decades-old routines. Companies are now in the process of revising their approach to biomedical research, focusing more on the disease and considering next-generation modalities such as programmable biology. ZS expert John Piccone explores what’s next for R&D and why he’s excited for companies taking this next step.